Cargando…
Effects of sclerostin antibody on bone healing
Promoting bone healing after a fracture has been a frequent subject of research. Recently, sclerostin antibody (Scl-Ab) has been introduced as a new anabolic agent for the treatment of osteoporosis. Scl-Ab activates the canonical Wnt (cWnt)-β-catenin pathway, leading to an increase in bone formation...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472444/ https://www.ncbi.nlm.nih.gov/pubmed/34631449 http://dx.doi.org/10.5312/wjo.v12.i9.651 |
_version_ | 1784574730090577920 |
---|---|
author | Mihara, Atsushi Yukata, Kiminori Seki, Toshihiro Iwanaga, Ryuta Nishida, Norihiro Fujii, Kenzo Nagao, Yuji Sakai, Takashi |
author_facet | Mihara, Atsushi Yukata, Kiminori Seki, Toshihiro Iwanaga, Ryuta Nishida, Norihiro Fujii, Kenzo Nagao, Yuji Sakai, Takashi |
author_sort | Mihara, Atsushi |
collection | PubMed |
description | Promoting bone healing after a fracture has been a frequent subject of research. Recently, sclerostin antibody (Scl-Ab) has been introduced as a new anabolic agent for the treatment of osteoporosis. Scl-Ab activates the canonical Wnt (cWnt)-β-catenin pathway, leading to an increase in bone formation and decrease in bone resorption. Because of its rich osteogenic effects, preclinically, Scl-Ab has shown positive effects on bone healing in rodent models; researchers have reported an increase in bone mass, mechanical strength, histological bone formation, total mineralized callus volume, bone mineral density, neovascularization, proliferating cell nuclear antigen score, and bone morphogenic protein expression at the fracture site after Scl-Ab administration. In addition, in a rat critical-size femoral-defect model, the Scl-Ab-treated group demonstrated a higher bone healing rate. On the other hand, two clinical reports have researched Scl-Ab in bone healing and failed to show positive effects in the femur and tibia. This review discusses why Scl-Ab appears to be effective in animal models of fracture healing and not in clinical cases. |
format | Online Article Text |
id | pubmed-8472444 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-84724442021-10-07 Effects of sclerostin antibody on bone healing Mihara, Atsushi Yukata, Kiminori Seki, Toshihiro Iwanaga, Ryuta Nishida, Norihiro Fujii, Kenzo Nagao, Yuji Sakai, Takashi World J Orthop Minireviews Promoting bone healing after a fracture has been a frequent subject of research. Recently, sclerostin antibody (Scl-Ab) has been introduced as a new anabolic agent for the treatment of osteoporosis. Scl-Ab activates the canonical Wnt (cWnt)-β-catenin pathway, leading to an increase in bone formation and decrease in bone resorption. Because of its rich osteogenic effects, preclinically, Scl-Ab has shown positive effects on bone healing in rodent models; researchers have reported an increase in bone mass, mechanical strength, histological bone formation, total mineralized callus volume, bone mineral density, neovascularization, proliferating cell nuclear antigen score, and bone morphogenic protein expression at the fracture site after Scl-Ab administration. In addition, in a rat critical-size femoral-defect model, the Scl-Ab-treated group demonstrated a higher bone healing rate. On the other hand, two clinical reports have researched Scl-Ab in bone healing and failed to show positive effects in the femur and tibia. This review discusses why Scl-Ab appears to be effective in animal models of fracture healing and not in clinical cases. Baishideng Publishing Group Inc 2021-09-18 /pmc/articles/PMC8472444/ /pubmed/34631449 http://dx.doi.org/10.5312/wjo.v12.i9.651 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Minireviews Mihara, Atsushi Yukata, Kiminori Seki, Toshihiro Iwanaga, Ryuta Nishida, Norihiro Fujii, Kenzo Nagao, Yuji Sakai, Takashi Effects of sclerostin antibody on bone healing |
title | Effects of sclerostin antibody on bone healing |
title_full | Effects of sclerostin antibody on bone healing |
title_fullStr | Effects of sclerostin antibody on bone healing |
title_full_unstemmed | Effects of sclerostin antibody on bone healing |
title_short | Effects of sclerostin antibody on bone healing |
title_sort | effects of sclerostin antibody on bone healing |
topic | Minireviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472444/ https://www.ncbi.nlm.nih.gov/pubmed/34631449 http://dx.doi.org/10.5312/wjo.v12.i9.651 |
work_keys_str_mv | AT miharaatsushi effectsofsclerostinantibodyonbonehealing AT yukatakiminori effectsofsclerostinantibodyonbonehealing AT sekitoshihiro effectsofsclerostinantibodyonbonehealing AT iwanagaryuta effectsofsclerostinantibodyonbonehealing AT nishidanorihiro effectsofsclerostinantibodyonbonehealing AT fujiikenzo effectsofsclerostinantibodyonbonehealing AT nagaoyuji effectsofsclerostinantibodyonbonehealing AT sakaitakashi effectsofsclerostinantibodyonbonehealing |